投资逻辑： 近期医疗器械领域政策与产业动态密集，创新支持与国际化布局同步推进。国家药监局批准创新医疗器械持续增加， 优先审评目录聚焦脑机接口、高端影像设备等核心领域。同时医保局为手术机器人等相关医疗服务项目建立新的收费 标准，创新产品入院速度有望进一步提升。脑机接口、手术机器人、智能诊断、生物材料等多赛道迎来发展机遇，行 业迈入以临床价值为核心的新发展阶段，国产头部企业将迎来加速发展机遇。 创新药：赛诺菲/再生元的度普利尤单抗获 FDA 批准成为全球首款 AFRS 治疗药物，基于 LIBERTY-AFRS-AIMSIII 期临 床数据，该药在鼻窦混浊评分、鼻息肉缩小及嗅觉改善等关键终点上显著优于安慰剂，安全性与已获批的 CRSwNP 适 应症一致，为这一高复发率疾病提供了首个靶向 2 型炎症的非手术替代方案。 生物制品： 2026 年 2 月 24 日，联邦制药与诺和诺德联合发布 GLP-1/GIP/GCG 三靶点受体激动剂（三激动剂）UBT251 中国 II 期临床研究的主要结果，治疗 24 周后，UBT251 治疗组的平均体重降幅最高达 19.7%（-17.5kg）。全球已有多 款 GLP-1 三靶药物进 ...

《破界·领航：全球视野下的中国医械创新白皮书》是一份专为医疗器械经销商/代理商/企业量身打造的创新导航图。我们以全球视野+本土洞察，深度剖 析市场，致力于成为您发掘高潜力创新产品、规避风险、制定市场策略的权威决策参考。 四大核心价值 赋能经销商决策！ 01 打破信息壁垒！ * 聚焦心血管介入、手术机器人、医学影像、肿瘤消融、骨科、内窥镜、新型医用材料等16个高增长热门赛道。 *精选72款国内外具有代表性的创新医疗器械产品，从政策支持、市场前景、核心技术、临床应用、竞争格局、厂家实力进行全方位、多维度深度剖析。 * 打破信息壁垒、减少信息不对称，帮助医疗器械经销商，深度且全面地了解目前市面上的创新医疗器械产品。 白皮书部分目录页展示 深度拆解16大赛道72+标杆案例 03 政策先行, 国产创新医械"黄金时代"来临 | 2、高端化:首创性技术多赛道开花 | ... | | --- | --- | | 3、智能化:"人工智能+"应用广泛触及 | 1 | | 4、本土化:外企本土化布局进阶提速 | 4 | | 5、精准化:迈向精准化大势所趋 | 5 | 02 赛道纵观, 创新医械细分领域趋势详解 | 1、IVD:从新 ...

经济观察网碧迪医疗(BDX.N)于2026年2月11日股价上涨4.72%，收盘报179.78美元。此次上涨主要与公 司最新财报表现、分析师评级调整及市场情绪改善相关。 业绩经营情况 根据2025财年第四季度财报，公司营收达58.9亿美元，同比增长8%，调整后每股收益为3.96美元，高于 华尔街平均预期。全年营收218.4亿美元，同比增长8.2%，盈利能力持续改善。财报显示生命科学业务 呈现复苏迹象，诊断解决方案业务在季度内重返正增长轨道。 机构观点 2026年2月10日至11日，多家机构更新评级。TD Cowen将目标价从183美元上调至189美元，维持"持 有"评级；花旗维持"买入"评级，目标价232美元为当前机构预测中的较高水平。市场对公司在生命科学 业务出售后的聚焦策略表示关注。 行业政策与环境 以上内容基于公开资料整理，不构成投资建议。 医疗器械板块近期受政策及创新主题催化。2026年2月10日中国国际医疗设备与器械交易平台上线，推 动行业全球化预期。同时，公司自身现金流稳健，2025财年自由现金流达26.7亿美元，支撑股息支付。 ...

Group 1 - The Chinese government has announced 2026 as the "Year of China-Laos Friendship" and will initiate a series of celebratory activities [1] - In 2025, China's service trade is expected to grow steadily, with total service import and export amounting to 80,823.1 billion yuan, a year-on-year increase of 7.4% [2] - The State Administration for Market Regulation reported that in 2025, 21 key technological bottlenecks in the industrial chain will be broken, and 71 quality technology gaps will be filled, with 4,929 national standards published, a year-on-year increase of 56% [2] Group 2 - On the fourth day of the Spring Festival travel rush, the expected cross-regional population flow is 1,964 million, a month-on-month increase of 3.4% [3] - The China Logistics and Purchasing Federation reported that the logistics industry prosperity index for January is 51.2%, indicating continued expansion in logistics business [3] - The January commodity price index reached 125.3 points, a month-on-month increase of 6.3%, marking the highest level since July 2022 [4] Group 3 - In 2025, China's gold production is projected to be 381.339 tons, a year-on-year increase of 1.09%, while gold consumption is expected to decline by 3.57% to 950.096 tons [4] - The China Machinery Industry Federation forecasts that the value added of large-scale enterprises in the machinery industry will grow by 8.2% year-on-year in 2025, outpacing national industrial and manufacturing growth rates by 2.3 and 1.8 percentage points respectively [4] - The World Health Organization has launched a global emergency fundraising appeal for 2026, aiming to raise approximately $1 billion to address 36 global health emergencies [4] Group 4 - The European Parliament has decided to resume legislative work on the approval of the US-EU trade agreement proposals [5] - According to the latest data from the Federal Statistical Office of Germany, the labor population aged 55 to 64 in Germany accounts for 24%, significantly higher than the EU average of 20.1%, making Germany the oldest labor population in the EU [5] Group 5 - Following the merger of SpaceX and xAI, Elon Musk's personal wealth has surpassed $800 billion, marking the fourth time in four months that he has set a new personal wealth record [6] - The Ministry of Finance and other departments have announced a "zero tariff" policy for imported goods consumed by residents in Hainan Free Trade Port, with a tax exemption limit of 10,000 yuan per person per year, with no limit on purchase frequency [6] - In 2025, 76 innovative medical devices are expected to be approved for market, representing a year-on-year increase of 17% [6] Group 6 - By December 2025, the number of internet users in China is expected to reach 1.125 billion, with the internet penetration rate exceeding 80% [7]

Core Insights - The global medical device market is projected to grow at a rate of approximately 6% annually, with a shift towards high-growth segments as multinational corporations divest slower-growing businesses [1] - Ten high-growth product segments have been identified, each with a market growth rate exceeding 15%, driven by innovative products that significantly outperform their peers [1] Group 1: Pulsed Field Ablation (PFA) - PFA has achieved over 20% penetration in the U.S. electrophysiology market within two years, with a market size exceeding $2 billion, making it one of the fastest-growing segments historically [2][4] - Major players like Boston Scientific and Medtronic are heavily investing in PFA commercialization, with Medtronic's PFA revenue expected to reach $1 billion in FY2025 and increase by another $1 billion in FY2026 [4] - The PFA market is projected to exceed $13 billion with an annual growth rate of over 25%, with penetration expected to reach 80% by 2028 [5] Group 2: Single-Use Endoscopes - Single-use endoscopes have rapidly gained market share due to their ability to eliminate cross-infection risks associated with reusable endoscopes and significantly reduce hospital costs [6][8] - Ambu, a leader in the single-use endoscope market, reported over 25% revenue growth in urology, ENT, and gastrointestinal departments, with expectations of maintaining a compound growth rate exceeding 20% [8][9] - The global single-use endoscope market is expected to continue growing rapidly, driven by aging populations and increasing demand for safe, efficient, and cost-effective solutions [9] Group 3: Laparoscopic Surgical Robots - The laparoscopic surgical robot market has surpassed $10 billion, with an annual growth rate exceeding 20%, despite a penetration rate of less than 15% in global minimally invasive surgeries [10][12] - The Da Vinci surgical system, a market leader, has seen significant revenue growth, with a projected revenue of over $10 billion in 2025, reflecting a 21% year-on-year increase [13] - The domestic laparoscopic surgical robot market is also experiencing growth, with sales of 119 units in the first 11 months of 2025 and expectations for further expansion as regulatory barriers ease [13] Group 4: Continuous Glucose Monitoring (CGM) - CGM technology addresses chronic disease management challenges, providing continuous glucose monitoring for diabetes patients, with significant market growth driven by U.S. Medicare coverage [14][17] - Abbott's CGM sales are expected to exceed $8 billion in 2025, with a year-on-year growth rate of approximately 23%, while Dexcom anticipates revenues of $4.63 to $4.65 billion [17] - The domestic CGM market is entering an accelerated penetration phase, driven by local companies leveraging supply chain advantages and cost reductions [18] Group 5: Mechanical Thrombectomy - Mechanical thrombectomy is gaining attention with significant acquisitions, such as Inari Medical's $4.9 billion acquisition by Stryker, highlighting the long-term value of this segment [19][21] - Inari Medical reported a 52.3% year-on-year revenue growth in Q2 2025, while Penumbra is expected to achieve a revenue growth of 21.4% to 22.0% in Q4 2025 [21][22] - The domestic market for mechanical thrombectomy is also growing rapidly, with over 20% growth driven by a large patient base and technological advancements [22] Group 6: Transcatheter Mitral and Tricuspid Valve Therapies (TMTT) - TMTT is rapidly becoming a key growth area in cardiovascular treatment, with Abbott and Edwards Lifesciences reporting significant revenue increases in this segment [23][24] - The domestic market is expanding, with an increase in regulatory approvals for TMTT products, indicating a growing demand [24] Group 7: Bronchoscopic Surgical Robots - The bronchoscopic surgical robot market is entering a phase of large-scale commercialization, with significant advancements in technology improving diagnostic accuracy and treatment outcomes [25][27] - Major platforms have received FDA approval, with Ion platform installations reaching 905 units and a surgical volume increase of over 50% in 2025 [27][28] Group 8: Poly-L-Lactic Acid Microbeads (PLLA) - PLLA is experiencing rapid growth in the medical aesthetics market, driven by consumer preferences for natural and long-lasting anti-aging solutions [29][30] - The market is characterized by a competitive landscape where international brands lead, but domestic companies are quickly gaining market share through cost advantages [30] Group 9: Non-invasive Ventilators - The non-invasive ventilator market is witnessing strong growth, particularly in the U.S., driven by increased consumer health awareness and market restructuring [31][33] - Companies like ResMed and Yuyue Medical are reporting significant revenue growth, with ResMed's overseas revenue increasing by 52.96% [33] Group 10: Shockwave Intravascular Lithotripsy (IVL) - IVL has achieved over $1 billion in market size, addressing calcification issues in coronary interventions, with a penetration rate of approximately 10% in the U.S. [34][36] - The market is expected to expand further as more products are introduced, capitalizing on the significant clinical need for effective treatment options [36]

Financial Data and Key Metrics Changes - In Q4 2025, worldwide sales were $24.6 billion, an increase of 7.1% despite a 650 basis point headwind from Stelara [19] - For the full year 2025, worldwide sales reached $94.2 billion, reflecting a 5.3% increase, with U.S. growth at 6.9% and 3.4% outside the U.S. [20][21] - Net earnings for Q4 were $5.1 billion, with diluted earnings per share at $2.10, compared to $1.41 a year ago [20] - Full year adjusted net earnings were $26.2 billion, with adjusted diluted earnings per share at $10.79, an increase of 8.1% compared to 2024 [21] Business Line Data and Key Metrics Changes - Innovative Medicine sales for Q4 were $15.8 billion, up 7.9%, with significant contributions from oncology and immunology [22] - In oncology, Darzalex grew 24.1%, while Carvykti achieved sales of $555 million with 63.2% growth [22] - Tremfya in immunology saw remarkable growth of 65.4%, while Stelara declined 48.6% due to biosimilar competition [23] - MedTech sales for the year were $34 billion, with operational growth of 5.4%, driven by cardiovascular and surgical segments [15][24] Market Data and Key Metrics Changes - In oncology, operational sales growth was 21% in 2025, with expectations to exceed $50 billion in annual sales by 2030 [10] - The cardiovascular segment delivered 15% operational sales growth, with Abiomed and Shockwave showing strong performance [15][16] - Vision care saw robust growth, particularly in surgical vision, with a 10.8% increase driven by new product innovations [17] Company Strategy and Development Direction - The company plans to separate its orthopedics business to focus on high-growth areas [7] - Investments of over $32 billion in R&D and M&A in 2025, including acquisitions of Intra-Cellular Therapies and HALDA Therapeutics, are aimed at accelerating growth [8] - The company aims for double-digit growth by the end of the decade, supported by a diverse portfolio of 28 products generating over $1 billion annually [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in accelerated growth for 2026, driven by a strong portfolio and pipeline [8][30] - The company anticipates operational sales growth of 5.7%-6.7% for 2026, with a midpoint of $100 billion [32] - Management highlighted the importance of innovation in driving future growth, particularly in oncology and immunology [45][50] Other Important Information - The company ended 2025 with approximately $20 billion in cash and marketable securities, generating $19.7 billion in free cash flow [31] - The effective tax rate for Q4 2025 was a benefit of 3%, compared to an 11.7% cost in Q4 2024 [27] - Adjusted income before tax as a percentage of sales increased from 24.1% to 28.7% [28] Q&A Session Summary Question: Overview of growth prospects and strategic repositioning - Analyst inquired about the key levers for achieving double-digit growth and the impact of the orthopedics separation on the company's strategy [43] - Management responded that the focus on oncology, immunology, and MedTech will drive growth, with a strong pipeline supporting this outlook [44][45] Question: MedTech market dynamics and growth expectations - Analyst asked about the MedTech market outlook for 2026 and the performance of the electrophysiology business [53] - Management indicated confidence in growth despite market dynamics, emphasizing strong clinical demand and successful product launches [54][60] Question: Margin progression and relationship to top-line growth - Analyst sought clarification on margin expansion in relation to expected sales growth [62] - Management noted that margin improvements are expected to align with sales growth, particularly post-orthopedic separation [66] Question: Vision care market health and performance - Analyst requested insights on the vision care segment's performance and market dynamics [69] - Management confirmed strong underlying performance in the contact lens category, with a focus on innovation and growth in vision care [70]

近日，由国家药监局器审中心牵头，山东省药监局主办的"春雨行动—医疗器械临床研究成果转化推进会"在济南召开。滕州市中心人 民医院器械科报送的"高流量吸氧雾化设备"项目成功入选山东省"春雨行动"重点项目，该项目也是全省唯一一个由县级医院独立申报 并入选的重点项目，标志着该院在医疗器械临床创新与成果转化领域取得重要突破。 | 51 | 多目标智能自适应脑机接口康 | 威海市立医院 | | --- | --- | --- | | | 复系统 | | | 52 | 微创脊柱外科远程手术机器人 | 山东大学 | | રે રે | 腰椎失稳智能辅助诊断软件 | 山东大学第二医院 | | ર્સ | 骨科医学影像智能测量软件 | 山东大学第二医院 | | રે રે | 三维正脊数字化系统 | 山东第一医科大学(山东省医学科学 | | | | 院) | | 56 | 上消化道早期肿瘤内镜影像辅 | 青岛美迪康数字工程有限公司 | | | 助诊断软件 | | | 57 | 腔内伤口测量系统 | 青岛市市立医院 | | રે 8 | 多模态影像智能诊断平台 | 威海市妇幼保健院 | | રે તે | AI 全自动光谱式高通量 ...

生物医药与健康产业是珠海"4+3"产业集群的重要组成部分，相关企业的发展备受珠海社会各界关注。1 月8日，归创通桥医疗科技股份有限公司在珠海高新区通桥医疗创新基地，举办投资者开放日活动，围 绕行业发展趋势、公司战略布局及创新产品进展展开深入探讨。 归创通桥董事长赵中介绍公司情况。 据悉，本次活动所在的珠海创新基地，于2022年动工建设，并于近期实现建成投产。项目占地约16000 ㎡，规划总建筑面积约58000㎡，计划总投资20亿元，建设涵盖研发厂房、办公及宿舍等功能配套，主 要针对几十项产品的研发、取证及规模化生产，搭建颅内植介入支架成型及加工、导管成型及制造、弹 簧圈等多条生产线。 赵中表示，该项目是公司集研发、制造与产业化于一体的重要平台，为公司推进创新成果转化及全球化 发展提供了坚实支撑。"项目能够满足我们接下来的产能需求，为公司的全方位发展奠定了很好的基 础。我们也很高兴能借此契机，向投资人和业界朋友展示我们的全新面貌。" 立足珠海十年，公司对珠海的产业发展环境有何评价？赵中表示："珠海城市环境很好，高新区也有各 种各样的优惠政策，对公司的发展与基地的建设给予了大力支持，我们很感谢政府部门这么多年对我 ...

Market Overview - The Shanghai Composite Index rose by 1.38% to close at 4023.42 points, with a daily high of 4025.26 points [1] - The Shenzhen Component Index increased by 2.24% to close at 13828.63 points, reaching a high of 13828.97 points [1] - The ChiNext Index saw a rise of 2.85%, closing at 3294.55 points, with a peak of 3295.29 points [1] ETF Market Performance - The median return of stock ETFs was 2.12%, with the highest return from the Southern CSI Star Market 50 ETF at 4.85% [2] - The highest performing industry index ETF was the China Securities All Index Medical Devices ETF, yielding 6.95% [2] - The highest return among thematic index ETFs was from the Ping An CSI Hong Kong-Shanghai Online Consumption Theme ETF at 6.94% [2] ETF Gains and Losses - The top three ETFs by gain were: - China Securities All Index Medical Devices ETF (6.95%) - Ping An CSI Hong Kong-Shanghai Online Consumption Theme ETF (6.94%) - Yongying CSI All Index Medical Devices ETF (6.37%) [5] - The top three ETFs by loss were: - China Securities Tourism Theme ETF (-1.35%) - Fortune CSI Tourism Theme ETF (-1.11%) - Penghua CSI 800 Free Cash Flow ETF (-0.78%) [6] ETF Fund Flows - The top three ETFs by fund inflow were: - Southern CSI 500 ETF (28.42 billion) - Huatai-PB CSI 300 ETF (11.02 billion) - Southern CSI Shenwan Nonferrous Metals ETF (9.15 billion) [8] - The top three ETFs by fund outflow were: - Southern CSI A500 ETF (12.88 billion) - Huaan ChiNext 50 ETF (9.97 billion) - Huatai-PB CSI A500 ETF (8.82 billion) [9] ETF Margin Trading Overview - The highest margin buy amounts were for: - Huatai-PB CSI 300 ETF (0.776 billion) - China Securities Star Market 50 ETF (0.682 billion) - Guotai Junan CSI All Index Securities Company ETF (0.47 billion) [11] - The highest margin sell amounts were for: - Huatai-PB CSI 300 ETF (63.87 million) - China Securities Star 50 ETF (34.55 million) - Southern CSI 500 ETF (23.85 million) [12] Institutional Insights - Century Securities suggests focusing on the transformation progress of leading companies in the medical device sector, which has gained market share post centralized procurement [13] - Guojin Securities emphasizes investment strategies in the medical device sector should focus on overseas expansion and innovation, as these areas provide additional growth opportunities and support profit margins during price declines in traditional businesses [14]

Group 1 - The A-share medical device sector experienced a significant increase, with the industry index rising by 5.64% on January 5, 2025, and over 60 billion yuan of net inflow from major funds into the sector [1] - The National Medical Products Administration (NMPA) announced adjustments to the management categories of 31 types of medical devices, introducing new categories and refining existing classifications to better align with technological advancements and regulatory needs [1] - The adjustments include the addition of innovative medical devices such as biodegradable magnesium metal clips and tendon repair patches, while also simplifying regulations for low-risk products like manual wheelchairs [1] Group 2 - Recent favorable policies have emerged for the medical device industry, including the NMPA's initiatives to optimize lifecycle regulation and prioritize the approval of high-end medical devices, which aim to accelerate the registration process and market entry [2] - The medical device industry is experiencing growth driven by policy support and market demand, leading to trends such as industry consolidation, increased market concentration, and ongoing investment in research and development [2] - China's medical device export volume continues to grow, with a total export value of 24.1 billion USD in the first half of 2025, reflecting a 5% increase compared to the same period in 2024 [2] Group 3 - Century Securities noted that domestic medical device manufacturers have gained significant market share following extensive centralized procurement, which is expected to benefit from scale effects and export policies [3] - Among the 133 listed companies in the A-share medical device sector, over 70% of those disclosing overseas revenue reported year-on-year growth, with six companies exceeding 1 billion yuan in overseas revenue in the first half of 2025 [3] - Mindray Medical's overseas revenue has consistently increased from 2.615 billion yuan in 2014 to 16.434 billion yuan in 2024, with international revenue expected to account for approximately 50% of total revenue in the first half of 2025 [3] Group 4 - Medical device companies are increasingly focusing on research and development, with 67 companies reporting R&D expenses exceeding 20% of their operating income, indicating a strong commitment to innovation within the sector [4] - Companies like Zhijiang Biology are making significant advancements in core technologies, including nanomagnetic beads and membrane materials, contributing to progress in cutting-edge areas such as membrane technology and organ-on-a-chip systems [5]